Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance - the Chennai Urban Rural Epidemiology Study (CURES)
Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance - the Chennai Urban Rural Epidemiology Study (CURES)
复制标题
DOI：
10.1016/j.metabol.2006.05.008
复制
发表时间：
2006-09-01
影响因子：
9.8
通讯作者：
Mohan, Viswanathan
中科院分区：
文献类型：
--
作者：
Deepa, Raj;Vehnurugan, Kaliyaperumal;Mohan, Viswanathan
这项横断面研究的目的是评估南印度城市受试者胰岛素抵抗 (IR) 与炎症分子 C 反应蛋白 (CRP)、白细胞介素 6 (IL-6)、血管细胞粘附分子 I (VCAM-1) 和单核细胞趋化蛋白 I (MCP-1) 的关系。以下组是从基于人群的钦奈城乡流行病学研究中选出的：第一组由 50 名糖耐量正常但无 IR 的健康受试者组成；第 2 组由 50 名患有 IR 的正常耐糖受试者组成，其定义为 IR 稳态模型评估 (HOMA-IR)；第 3 组由 50 名患有糖耐量受损 (IGT) 的受试者组成；第 4 组和第 5 组分别由 50 名新诊断和已知的 2 型糖尿病受试者组成。纳入标准包括不吸烟者；正常静息 12 导联心电图；没有心绞痛、心肌梗塞或任何已知的血管、感染或炎症疾病史，并且未服用他汀类药物或阿司匹林。无 IR 的正常糖耐量的 CRP、IL-6 和 VCAM-I 值最低（CRP，1.32 mg/L；IL-6，12.56 pg/mL；VCAM-1，277 pg/mL），其次是 IR 的正常糖耐量（CRP，2.25 mg/L；IL-6，20.97 pg/mL；VCAM-1，289 pg/mL）、葡萄糖受损耐受性（CRP，2.37 mg/L；IL-6，22.11 pg/mL；VCAM-1，335 pg/mL），新诊断糖尿病受试者（CRP，3.24 mg/L；IL-6，23.21 pg/mL；VCAM-1，568 pg/mL），最高水平出现在已知糖尿病受试者（CRP，4.08 mg/L；IL-6， 29.44 皮克/毫升；VCAM-1，577 皮克/毫升）。这一趋势具有统计显着性（P
The aim of this cross-sectional study was to assess the association of insulin resistance (IR) with inflammatory molecules C-reactive protein (CRP), interleukin 6 (IL-6), vascular cell adhesion molecule I (VCAM-1), and monocyte chemotactic protein I (MCP-1) in urban South Indian subjects. The following groups were selected from the population-based Chennai Urban Rural Epidemiology Study: group I composed of 50 healthy subjects with normal glucose tolerance without IR; group 2 consisted of 50 normal glucose-tolerant subjects with IR as defined by homeostasis model assessment of IR (HOMA-IR); group 3 consisted of 50 subjects with impaired glucose tolerance (IGT); and groups 4 and 5 each comprised 50 newly diagnosed and known type 2 diabetic subjects, respectively. The inclusion criteria included nonsmokers; normal resting 12-lead electrocardiogram; and absence of angina, myocardial infarction, or history of any known vascular, infectious, or inflammatory diseases, and not on statins or aspirin. Normal glucose tolerance without IR had the lowest values of CRP, IL-6, and VCAM-I (CRP, 1.32 mg/L; IL-6, 12.56 pg/mL; VCAM-1, 277 pg/mL) followed by normal glucose tolerance with IR (CRP, 2.25 mg/L; IL-6,20.97 pg/mL; VCAM-1, 289 pg/mL), impaired glucose tolerance (CRP, 2.37 mg/L; IL-6,22.11 pg/mL; VCAM-1, 335 pg/mL), newly diagnosed diabetic subjects (CRP, 3.24 mg/L; IL-6, 23.21 pg/mL; VCAM-1, 568 pg/mL), and the highest levels were in the known diabetic subjects (CRP, 4.08 mg/L; IL-6, 29.44 pg/mL; VCAM-1, 577 pg/mL). This trend was statistically significant (P